Coherus Oncology, Inc.
Coherus Oncology, Inc. (CHRS) Stock Overview
Explore Coherus Oncology, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
198M
P/E Ratio
1.24
EPS (TTM)
$-1.56
ROE
7.89%
CHRS Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Coherus Oncology, Inc. (CHRS) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 49.86, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.52.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 1.24 and a market capitalization of 198M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.